Cryo-Cell Confirms Specimen Longevity Of 23+ Years with Optimal CD34 Viability
OLDSMAR, FL – March 4, 2020 – Cryo-Cell International’s
March 4, 2020
announcement is concurrent with the most recent research regarding the lifespan of stored cord blood performed by Dr. Hal Boxmeyer and colleagues, which determined sample viability of 23.5 years and suggested possible, indefinite length of storage time for cryogenically preserved cells under proper conditions.11
Cryo-Cell International marks the first family cord blood bank to release results concerning specimen viability for this length of time.
Since cord blood banking has only been in existence for 30 years, these findings indicate that specimen longevity nearly spans the lifetime of the industry. Research points to the idea that other cryogenically preserved cells remain undiminished by time, as long as cells are preserved at optimal storage temperature, where cellular activity is known to halt. Cryo-Cell International, Inc., stands as the only private use cord blood bank in the U.S. to receive the Foundation for the Accreditation for Cellular Therapy (FACT) accreditation, which addresses all quality aspects of cord blood collection, processing, testing, banking, selection and release of specimens.
Todd Schuesler, Director of Cryo-Cell International’s laboratory and cryopreservation facility, noted, “Cryo-Cell is accredited by FACT, AABB, and ISO13485, making us one of the most accredited cord blood banks in the U.S. These accreditations are only awarded to organizations with exceptional quality systems and acute commitment to customer care. It’s our employees who make the difference; for many, it is personal, based on previous or current experiences with diseases that can or will potentially be treated with stem cells.” Having access to cord blood and cord tissue for the treatment of diseases developed much later in life will prove to be invaluable as evolving research continues to reveal potential uses.
“These are simply amazing results that validates our belief that, if properly processed and maintained at the proper temperature, cryogenically preserved cord blood stem cells can provide regenerative benefits for at least the baby’s lifetime and likely for generations thereafter,” said David Portnoy, Cryo-Cell International’s Chairman and Co-CEO. Currently, cord blood stem cells have been FDA-approved for standard treatment in nearly 80 diseases. Numerous clinical trials are underway to explore the use of umbilical stem cells in the treatment of various degenerative conditions, including autism and cerebral palsy.
About Cryo-Cell International, Inc.
Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank. More than 500,000 parents from 87 countries trust Cryo-Cell to preserve their family members' stem cells. Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is FDA registered, cGMP-/cGTP-compliant, and is licensed in all states requiring licensure. Besides being AABB accredited as a cord blood facility, Cryo-Cell is also the first U.S. (for private use only) cord blood bank to receive FACT accreditation for adhering to the most stringent cord blood quality standards set by any internationally recognized, independent accrediting organization. In addition, Cryo-Cell is ISO 9001:2008 certified by BSI, an internationally recognized, quality assessment organization. Cryo-Cell is a publicly-traded company, OTCQB:CCEL. For more information, please visit www.cryo-cell.com
. For a complete list of references, visit www.cryo-cell.com/references
Statements wherein the terms "believes", "intends", "projects", "anticipates", "expects", and similar expressions as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company, which include future medical and research developments.The Company disclaims any obligations to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements.